Skip to main content

Table 4 Clinicopathologic characteristics according to histologic subtypes

From: Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study

Characteristics Endometrioid
(n = 18, %)
Non-endometrioid
(n = 14, %)
P-value
Age at diagnosis, years    0.354
  Median (range) 56 (43–77) 57 (34–68)  
Menopausal status    0.960
  Premenopause 5 (27.8) 4 (28.6)  
  Postmenopause 13 (72.2) 10 (71.4)  
Grade    < 0.001
  Low 11 (61.1)   
  High 7 (38.9)   
  Not applicable   14 (100)  
FIGO stage    0.788
  IIIC 2 (11.1) 2 (14.3)  
  IVB 16 (88.9) 12 (85.7)  
CA-125 at diagnosis, IU/ml    0.417
  Median (range) 181.7 (12.2–3489.0) 193.6 (8.6–1800.0)  
CA-125 after NAC, IU/ml    0.417
  Median (range) 17.3 (7.0–1490.0) 25.8 (7.0–391.0)  
NAC regimen    0.232
  Paclitaxel-carboplatin 15 (83.3) 10 (71.4)  
  Doxorubicin-cisplatin 0 2 (14.3)  
  Paclitaxel-cisplatin-bevacizumab 2 (11.1) 0  
  Ifosfamide-cisplatin 1 (5.6) 1 (7.1)  
  Etoposide-cisplatin 0 1 (7.1)  
Number of NAC cycles    0.616
  Median (range) 6 (2–12) 6 (2–12)  
  2–3 6 (33.3) 5 (35.7)  
  4–6 7 (38.9) 3 (21.4)  
  ≥7 5 (27.8) 6 (42.9)  
Response to NAC    0.982
  CR 1 (5.6) 1 (7.1)  
  PR 14 (77.8) 10 (71.4)  
  SD 2 (11.1) 2 (14.3)  
  PD 1 (5.6) 1 (7.1)  
Residual tumor after IDS    0.158
  No gross residual 12 (66.7) 11 (78.6)  
  < 1 cm 6 (33.3) 1 (7.1)  
  ≥ 1 cm 0 2 (14.3)  
  1. Abbreviations: FIGO International Federation of Gynecology and Obstetrics, NAC Neoadjuvant chemotherapy, IDS Interval debulking surgery, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease